ESR1 and breast cancer: Furthermore, the results of in silico analyses, together with our in vitro data reported recently, attest that StAR can serve as a novel prognostic marker in ER+/PR+ breast cancer, whereas its inhibition, involving E2 synthesis, by a number of histone deacetylase inhibitors, might have therapeutic implications in the prevention/treatment of this devastating disease.